The semaglutide impurity des-1-His, 2-Aib, 3-Glu, 4-Gly-SMT is an N-terminal truncated defective body produced during the synthesis or degradation process of semaglutide. Semaglutide is a long-acting GLP-1 analogue widely used in the treatment of type 2 diabetes and obesity. The impurity is characterized by the lack of the first four key amino acid residues at the N-terminus (1-histidine, 2-aminoisobutyric acid, 3-glutamic acid and 4-glycine). This structural deficiency may cause it to lose its GLP-1 receptor binding activity, thereby affecting the efficacy of the drug. In drug development and quality control, such process-related impurities need to be strictly monitored to ensure the purity and therapeutic safety of the final product.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-Ala-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HATFTSDVSSYLEGQAAKEFIAWLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C176H266N45O50S |
Molecular weight |
3798.08 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |